Aliases & Classifications for Hidradenitis

MalaCards integrated aliases for Hidradenitis:

Name: Hidradenitis 12 45 15 74
Hydradenitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2282
ICD9CM 36 705.83
MeSH 45 D016575
NCIt 51 C112190
SNOMED-CT 69 69741000
UMLS 74 C0085160

Summaries for Hidradenitis

Disease Ontology : 12 A sweat gland disease that is characterized by inflammation of the apocrine sweat glands and has symptom erythema, edema, papules, plaques, pruritis, and pain.

MalaCards based summary : Hidradenitis, also known as hydradenitis, is related to hidradenitis suppurativa and pyoderma gangrenosum, and has symptoms including erythema An important gene associated with Hidradenitis is NCSTN (Nicastrin), and among its related pathways/superpathways are Developmental Biology and Th17 cell differentiation. The drugs Adalimumab and Anti-Inflammatory Agents have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, skin and testes, and related phenotypes are craniofacial and hematopoietic system

Related Diseases for Hidradenitis

Diseases related to Hidradenitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 219)
# Related Disease Score Top Affiliating Genes
1 hidradenitis suppurativa 31.1 DSC2 DSG2 IL12RB1 IL17A KRT10 KRT14
2 pyoderma gangrenosum 31.0 NOD2 TNF
3 pyoderma 31.0 NOD2 TNF
4 spondyloarthropathy 30.6 IL17A TNF
5 arthritis 30.5 IL17A NOD2 TNF
6 inflammatory bowel disease 30.5 IL17A NOD2 TNF
7 crohn's colitis 30.3 NOD2 TNF
8 colitis 30.1 IL17A NOD2 TNF
9 ulcerative colitis 30.1 IL17A NOD2 TNF
10 spondylarthropathy 30.0 NOD2 TNF
11 spondyloarthropathy 1 29.9 IL17A NOD2 TNF
12 spondylitis 29.9 IL17A NOD2 TNF
13 melkersson-rosenthal syndrome 29.9 NOD2 TNF
14 dowling-degos disease 29.8 DSC2 KRT14 NCSTN PSENEN
15 skin disease 29.7 IL17A KRT10 KRT14 TNF
16 alzheimer disease 29.5 NCSTN PSEN1 PSENEN TNF
17 pyoderma gangrenosum-acne-suppurative hidradenitis syndrome 12.3
18 perifolliculitis capitis abscedens et suffodiens, familial 11.5
19 acne inversa, familial, 1 11.4
20 papillon-lefevre syndrome 11.1
21 acne inversa, familial, 2, with or without dowling-degos disease 11.1
22 acne inversa, familial, 3 11.1
23 squamous cell carcinoma 10.6
24 neurofibromatosis, type ii 10.5
25 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 10.5
26 crohn's disease 10.4
27 sebaceous gland disease 10.4 NCSTN PSENEN
28 psoriasis 10.3
29 miller fisher syndrome 10.3 PSENEN TNF
30 ileocolitis 10.3 NOD2 TNF
31 granulomatous dermatitis 10.3 NOD2 TNF
32 inflammatory bowel disease 3 10.3 NOD2 TNF
33 streptococcal meningitis 10.3 NOD2 TNF
34 ocular toxoplasmosis 10.3 IL17A NOD2
35 orofacial granulomatosis 10.3 NOD2 TNF
36 trichosporonosis 10.3 IL17A TNF
37 central nervous system vasculitis 10.2 IL17A TNF
38 blau syndrome 10.2 NOD2 TNF
39 sweat gland disease 10.2 KRT14 NCSTN
40 autoimmune disease of eyes, ear, nose and throat 10.2 IL17A TNF
41 transverse myelitis 10.2 IL17A TNF
42 dowling-degos disease 1 10.2
43 malignant atrophic papulosis 10.2
44 myelitis 10.2 IL17A TNF
45 primary systemic mycosis 10.2 IL17A TNF
46 mycoplasma pneumoniae pneumonia 10.2 IL17A TNF
47 anal canal squamous cell carcinoma 10.2 NCSTN PSEN1 PSENEN
48 stromal keratitis 10.2 IL17A TNF
49 hypersensitivity reaction type iv disease 10.2 NOD2 TNF
50 joint disorders 10.2 IL17A TNF

Graphical network of the top 20 diseases related to Hidradenitis:



Diseases related to Hidradenitis

Symptoms & Phenotypes for Hidradenitis

Symptoms:

12
  • erythema

MGI Mouse Phenotypes related to Hidradenitis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 craniofacial MP:0005382 9.55 IL17A KRT14 NCSTN PSEN1 TNF
2 hematopoietic system MP:0005397 9.5 IL12RB1 IL17A KRT14 NCSTN NOD2 PSEN1
3 immune system MP:0005387 9.17 IL12RB1 IL17A KRT14 NCSTN NOD2 PSEN1

Drugs & Therapeutics for Hidradenitis

Drugs for Hidradenitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adalimumab Approved Phase 4,Phase 3,Phase 2 331731-18-1 16219006
2 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
3 Anesthetics Phase 4,Phase 1
4 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
5 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
6 Anti-Bacterial Agents Phase 3,Phase 2,Not Applicable
7 Antibiotics, Antitubercular Phase 3,Not Applicable
8 Antibodies Phase 3,Phase 2,Phase 1,Early Phase 1
9 Immunoglobulins Phase 3,Phase 2,Phase 1,Early Phase 1
10 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1,Early Phase 1
11
Apremilast Approved, Investigational Phase 2 608141-41-9 11561674
12
Infliximab Approved Phase 2 170277-31-3
13
Etanercept Approved, Investigational Phase 2 185243-69-0
14
Ustekinumab Approved, Investigational Phase 2 815610-63-0
15
Hydroxychloroquine Approved Phase 1, Phase 2 118-42-3 3652
16
Drospirenone Approved Phase 2 67392-87-4 68873
17
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
18
Ethinyl Estradiol Approved Phase 2 57-63-6 5991
19
Polyestradiol phosphate Approved Phase 2 28014-46-2
20 Anti-Infective Agents Phase 2,Phase 1,Not Applicable
21 Immunosuppressive Agents Phase 2,Not Applicable
22 Dermatologic Agents Phase 2,Not Applicable
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2,Not Applicable
24 Hormone Antagonists Phase 2,Not Applicable
25 Hormones Phase 2,Not Applicable
26 Analgesics Phase 2
27 Analgesics, Non-Narcotic Phase 2
28 Anti-Inflammatory Agents, Non-Steroidal Phase 2
29 Angiogenesis Inhibitors Phase 2
30 Angiogenesis Modulating Agents Phase 2
31 Peripheral Nervous System Agents Phase 2,Not Applicable
32 Interleukin 1 Receptor Antagonist Protein Phase 2
33 Gastrointestinal Agents Phase 2
34 Complement System Proteins Phase 2
35 Antiparasitic Agents Phase 1, Phase 2
36 Antiprotozoal Agents Phase 1, Phase 2
37 Antimalarials Phase 1, Phase 2
38 lysine Phase 2
39 diuretics Phase 2
40 Diuretics, Potassium Sparing Phase 2
41 Estrogens Phase 2
42 Estradiol 17 beta-cypionate Phase 2
43 Estradiol 3-benzoate Phase 2
44 Drospirenone and ethinyl estradiol combination Phase 2
45 Mineralocorticoids Phase 2
46 Natriuretic Agents Phase 2
47 Contraceptive Agents Phase 2
48 Contraceptives, Oral Phase 2
49 Mineralocorticoid Receptor Antagonists Phase 2
50
Phenol Approved, Experimental Phase 1 108-95-2 996

Interventional clinical trials:

(show top 50) (show all 72)
# Name Status NCT ID Phase Drugs
1 Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS Recruiting NCT03221621 Phase 4 Adalimumab Injection
2 Safety and Efficacy of Humira (Adalimumab) for Hidradenitis Suppurativa (HS) Peri-Surgically (SHARPS Study) Active, not recruiting NCT02808975 Phase 4 Adalimumab;Placebo
3 Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa Completed NCT01468207 Phase 3
4 Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa Completed NCT01468233 Phase 3
5 Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa Completed NCT01635764 Phase 3
6 Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) Recruiting NCT03713632 Phase 3 Secukinumab
7 This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). Recruiting NCT03713619 Phase 3 secukinumab
8 Effect of Sclerotherapy on Fistulas and Sinus Tracts in Hidradenitis Suppurativa Recruiting NCT02805595 Phase 3 23.4% Hypertonic saline;Saline
9 Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa Active, not recruiting NCT02904902 Phase 3 adalimumab
10 To Determine the Efficacy of a Laser Device for the Treatment of Hidradenitis Suppurativa Terminated NCT00367328 Phase 3
11 A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa. Completed NCT03248531 Phase 2 Bimekizumab;Adalimumab
12 Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients Completed NCT02421172 Phase 2
13 Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa Completed NCT02695212 Phase 2 Apremilast
14 To Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT00827996 Phase 2 adalimumab
15 Anakinra as a Treatment for Hydradenitis Suppurativa Completed NCT01516749 Phase 2 anakinra
16 Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa Completed NCT00795574 Phase 2 infliximab;Placebo Comparator
17 Etanercept for Treatment of Hidradenitis Completed NCT00107991 Phase 2 etanercept
18 Etanercept in Hidradenitis Suppurativa Completed NCT00329823 Phase 2 Etanercept sc 50mg per week for 12 weeks
19 Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa Completed NCT03001622 Phase 2
20 Anakinra in Hidradenitis Suppurativa Completed NCT01558375 Phase 2 Water for injection;Anakinra
21 MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB Completed NCT02643654 Phase 2 MABp1;Placebo
22 A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa Completed NCT01704534 Phase 2 Ustekinumab
23 Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis Completed NCT03049267 Phase 2 Apremilast;Placebo Oral Tablet
24 Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa Completed NCT00918255 Phase 2 Placebo
25 A Study of Bermekimab in Patients With Hidradenitis Suppurativa Recruiting NCT03512275 Phase 2 Bermekimab Monoclonal Antibody 400 mg
26 Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa Recruiting NCT03852472 Phase 2 Avacopan
27 A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) Recruiting NCT03628924 Phase 2 Guselkumab dose 1;Guselkumab dose 2;Guselkumab dose 3;Placebo
28 A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa Recruiting NCT03607487 Phase 2 INCB054707;Placebo
29 A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa Recruiting NCT03569371 Phase 2 INCB054707
30 Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa Recruiting NCT03275870 Phase 1, Phase 2 Hydroxychloroquine
31 Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) Active, not recruiting NCT03487276 Phase 2 IFX-1;Placebo
32 Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa Not yet recruiting NCT03827798 Phase 2 CFZ533;Placebo to CFZ533;LYS006;Placebo to LYS006
33 Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa Terminated NCT01838499 Phase 2
34 A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS Terminated NCT00722800 Phase 2 drospirenone and ethinyl estradiol (YAZ);Placebo
35 Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa Completed NCT00134134 Phase 1 efalizumab
36 Endoscopic Pilonidal Sinus Treatment With Additional Crystalized Phenol Completed NCT02277340 Phase 1
37 Patients With Hidradenitis vs Patients With Psoriasis: Psychological Impact Unknown status NCT02999698
38 An Investigation Into the Efficacy of Provodine Topical Cream as Compared to 10% Benzoyl Peroxide Wash for the Treatment of Hidradenitis Suppurativa. Unknown status NCT01818167 Not Applicable 10% Benzoyl Peroxide Topical Body Wash;Provodine Topical Cream
39 Study to Compare Two Treatments for Axillary Hidradenitis Suppurativa: Carbon Dioxide Laser Versus Surgical Deroofing Unknown status NCT02163746 Not Applicable
40 Group Psychotherapy for Patients With Hidradenitis Suppurativa: Effects in Quality of Life Unknown status NCT02904408 Not Applicable
41 Trial Comparing Efficacy of Treatments for Hidradenitis Suppurativa Unknown status NCT01063270 Not Applicable Clindamycin & Rifampin
42 Efficacy of Percutaneous Injection of Triamcinolone in the Treatment of Mammillary Fistula Unknown status NCT01315080
43 Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Patients - a Multi cOuNtry studY in Real Life Setting Completed NCT02786576
44 Association Between Hidradenitis Suppurativa and Spondyloarthritis Completed NCT03668925 Not Applicable
45 A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurativa. Completed NCT02781818 Not Applicable Triamcinolone Acetonide 10mg/mL;Triamcinolone Acetonide 40mg/mL;Normal Saline
46 Study on the Effect of NdYag Laser for the Treatment of Hidradenitis Suppurativa Completed NCT00494351 Not Applicable
47 Pilot Study on Botulinum Toxin B as Treatment for Hidradenitis Suppurativa Completed NCT03103074 Not Applicable Botulinum B Toxin
48 Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients Completed NCT02739828
49 Quality of Life After Wide Surgical Excision in Patients With Hidradenitis Suppurativa Completed NCT02593604
50 Activation of a Cutaneous Inflammasome in the Skin of Hidradenitis Suppurativa Patients Completed NCT02833909 Not Applicable

Search NIH Clinical Center for Hidradenitis

Cochrane evidence based reviews: hidradenitis

Genetic Tests for Hidradenitis

Anatomical Context for Hidradenitis

MalaCards organs/tissues related to Hidradenitis:

42
Neutrophil, Skin, Testes, Breast, Thyroid, T Cells, Myeloid

Publications for Hidradenitis

Articles related to Hidradenitis:

(show top 50) (show all 1767)
# Title Authors Year
1
The associations of depression and coping methods on health-related quality of life for those with hidradenitis suppurativa. ( 30876533 )
2019
2
Hidradenitis suppurativa and diabetes mellitus: updated systematic review and adjusted meta-analysis. ( 30730068 )
2019
3
Isotretinoin and Hidradenitis Suppurativa. ( 30802991 )
2019
4
Hidradenitis Suppurativa and Diabetes: Big Data Bias Masks a True Association. ( 30802992 )
2019
5
Combination hyperbaric oxygen therapy and ustekinumab for severe hidradenitis suppurativa. ( 30805965 )
2019
6
Apremilast for the Treatment of Mild-to-Moderate Hidradenitis Suppurativa in a Prospective, Open-Label, Phase 2 Study ( 30811140 )
2019
7
Effectiveness, safety and tolerability of drainage and punch-trocar-assisted cryoinsufflation (cryopunch) in the treatment of inflammatory acute fluid collections in hidradenitis suppurativa patients. ( 30811686 )
2019
8
Reply to: "Could Isotretinoin flare Hidradentis suppurativa? A Case Series". ( 30816560 )
2019
9
Two-step surgery in extensive anogenital hidradenitis: What kind of faecal management? ( 30821118 )
2019
10
Squamous carcinoma over perineal hidradenitis suppurativa. ( 30825999 )
2019
11
Transcriptome Patterns in Hidradenitis Suppurativa: Support for the Role of Antimicrobial Peptides and Interferon Pathways in Disease Pathogenesis. ( 30828847 )
2019
12
A new Th-17 cytokine in hidradenitis suppurativa: antimicrobial and pro-inflammatory role of IL-26. ( 30829398 )
2019
13
Hidradenitis Suppurativa (Hurley I/II): Serial Excisions with Primary Wound Closure Under Local Anesthesia As Most Adequate Treatment Approach. ( 30834010 )
2019
14
Association Between Hidradenitis Suppurativa and Metabolic Syndrome. ( 30846164 )
2019
15
Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms. ( 30854183 )
2019
16
Commentary: Hidradenitis Suppurativa: A Systematic Review Integrating Inflammatory Pathways Into a Cohesive Pathogenic Model. ( 30858850 )
2019
17
North American Clinical Management Guidelines for Hidradenitis Suppurativa: a Publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Part II: Topical, Intralesional, and Systemic medical Management. ( 30872149 )
2019
18
Comment on "Interruption of oral clindamycin plus rifampicin therapy in patients with hidradenitis suppurativa: an observational study to assess prevalence and causes". ( 30872151 )
2019
19
Reply to "Comment on 'Interruption of oral clindamycin plus rifampicin therapy in patients with hidradenitis suppurativa: an observational study to assess prevalence and causes' ". ( 30872153 )
2019
20
North American Clinical Management Guidelines for Hidradenitis Suppurativa: a Publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Part I: Diagnosis, Evaluation, and the use of Complementary and Procedural Management. ( 30872156 )
2019
21
Lack of photographic documentation undermines assessment of Hidradenitis Suppurativa phenotypes. ( 30874297 )
2019
22
Assessing the Efficacy of New Biologic Therapies in Hidradenitis Suppurativa Consistency vs Bias in Outcome Measures in Moderate and Severe Disease. ( 30875132 )
2019
23
Reply to comment: Guselkumab in the treatment of severe hidradenitis suppurativa. ( 30875137 )
2019
24
Mast cells in hidradenitis suppurativa: a clinicopathological study. ( 30877368 )
2019
25
Treatment of Hidradenitis Suppurativa with Extensive Resection of the Lesion and Coverage with Perforator Flaps of the Lateral Thoracic Wall (Lateral Thoracic Artery, Thoracodorsal Artery Perforators). ( 30881834 )
2019
26
Hidradenitis Suppurativa: Estimated Prevalence, Clinical Features, Concomitant Conditions, and Diagnostic Delay in a University Teaching Hospital in Buenos Aires, Argentina. ( 30885385 )
2019
27
Commentary on Squamous Cell Carcinoma in Perineal, Perianal, and Gluteal Hidradenitis Suppurativa: Experience in 12 Patients. ( 30893153 )
2019
28
Defining Fistular Patterns in Hidradenitis Suppurativa: Impact in the Management. ( 30893168 )
2019
29
Metformin use in hidradenitis suppurativa. ( 30893570 )
2019
30
Patient Perspectives: What is hidradenitis suppurativa (HS)? ( 30895674 )
2019
31
Validation of a Hidradenitis Suppurativa Self-Assessment Tool. ( 30897946 )
2019
32
Neutrophilic eccrine hidradenitis secondary to pegfilgrastim in a patient with synovial sarcoma. ( 30899488 )
2019
33
Matrix remodeling and MMP expression/activation is associated with hidradenitis suppurativa skin inflammation. ( 30903721 )
2019
34
KITTEN following CAT on the long-term use of rifampicin in hidradenitis suppurativa and effectiveness of oral contraceptives. ( 30907428 )
2019
35
The microbiome of tunnels in hidradenitis suppurativa patients. ( 30908704 )
2019
36
Adalimumab Medium-Term Dosing Strategy in Moderate-to-Severe Hidradenitis Suppurativa: Integrated Results from the Phase 3, Randomized, Placebo-Controlled, PIONEER Trials. ( 30916379 )
2019
37
Even Mild Hidradenitis Suppurativa Impairs Quality of Life. ( 30916383 )
2019
38
Adolescent-Onset Hidradenitis Suppurativa: Prevalence, Risk Factors and Disease Features. ( 30368494 )
2019
39
Standardized Photographic Documentation of Hidradenitis Suppurativa/Acne Inversa. ( 30368496 )
2019
40
Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial. ( 30482392 )
2019
41
Hidradenitis suppurativa of the nape: Description of an atypical phenotype related to severe early-onset disease in men. ( 30561771 )
2019
42
A 12-Year Experience of Hidradenitis Suppurativa Management. ( 30570558 )
2019
43
Chitinase-3-like Protein 1 (YKL-40) Is Expressed in Lesional Skin in Hidradenitis Suppurativa. ( 30587614 )
2019
44
Hidradenitis suppurativa. ( 30589737 )
2019
45
Clindamycin alone may be enough. Is it time to abandon rifampicin for hidradenitis suppurativa? ( 30604861 )
2019
46
Clindamycin alone may be enough. Is it time to abandon rifampicin for hidradenitis suppurativa? Reply from the authors. ( 30604869 )
2019
47
High-frequency ultrasound in hidradenitis suppurativa as rationale for permanent hair laser removal. ( 30609069 )
2019
48
Interruption of oral clindamycin plus rifampicin therapy in patients with hidradenitis suppurativa: an observational study to assess prevalence and causes. ( 30630028 )
2019
49
HIDRAdisk: validation of an innovative visual tool to assess the burden of hidradenitis suppurativa. ( 30633405 )
2019
50
Ixekizumab in hidradenitis suppurativa: a case report in a psoriatic patient. ( 30636397 )
2019

Variations for Hidradenitis

Expression for Hidradenitis

Search GEO for disease gene expression data for Hidradenitis.

Pathways for Hidradenitis

Pathways related to Hidradenitis according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.01 DSC2 DSG2 KRT10 KRT14 NCSTN PSENEN
2
Show member pathways
12.32 IL12RB1 IL17A NOD2 TNF
3
Show member pathways
12.19 DSC2 DSG2 KRT10 KRT14
4 11.98 NCSTN PSEN1 PSENEN
5
Show member pathways
11.94 NCSTN PSEN1 PSENEN
6 11.84 NCSTN PSEN1 PSENEN
7
Show member pathways
11.78 IL12RB1 IL17A TNF
8 11.54 IL12RB1 IL17A TNF
9
Show member pathways
11.4 NCSTN PSEN1 PSENEN
10 11.24 NCSTN PSEN1 PSENEN
11 11.06 IL17A TNF
12 10.99 NCSTN PSEN1 PSENEN
13 10.89 NOD2 TNF
14 10.49 NCSTN PSEN1 PSENEN
15 10.07 PSEN1 PSENEN
16 10.03 NCSTN PSEN1 PSENEN

GO Terms for Hidradenitis

Cellular components related to Hidradenitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.56 DSG2 NOD2 PSEN1 TNF
2 desmosome GO:0030057 9.16 DSC2 DSG2
3 cornified envelope GO:0001533 9.13 DSC2 DSG2 KRT10
4 gamma-secretase complex GO:0070765 8.8 NCSTN PSEN1 PSENEN

Biological processes related to Hidradenitis according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 Notch signaling pathway GO:0007219 9.74 NCSTN PSEN1 PSENEN
2 keratinization GO:0031424 9.73 DSC2 DSG2 KRT10 KRT14
3 positive regulation of catalytic activity GO:0043085 9.69 NCSTN PSEN1 PSENEN
4 cornification GO:0070268 9.67 DSC2 DSG2 KRT10 KRT14
5 positive regulation of MAP kinase activity GO:0043406 9.65 NOD2 PSEN1 TNF
6 protein processing GO:0016485 9.63 NCSTN PSEN1 PSENEN
7 regulation of heart rate by cardiac conduction GO:0086091 9.61 DSC2 DSG2
8 positive regulation of interleukin-8 production GO:0032757 9.6 NOD2 TNF
9 regulation of synaptic transmission, glutamatergic GO:0051966 9.59 PSEN1 TNF
10 positive regulation of osteoclast differentiation GO:0045672 9.58 IL17A TNF
11 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.58 IL17A NOD2
12 membrane protein ectodomain proteolysis GO:0006509 9.58 NCSTN PSEN1 PSENEN
13 amyloid-beta metabolic process GO:0050435 9.56 NCSTN PSEN1
14 epithelial cell proliferation GO:0050673 9.55 NCSTN PSEN1
15 regulation of ventricular cardiac muscle cell action potential GO:0098911 9.54 DSC2 DSG2
16 astrocyte activation GO:0048143 9.52 PSEN1 TNF
17 amyloid precursor protein metabolic process GO:0042982 9.5 NCSTN PSEN1 PSENEN
18 bundle of His cell-Purkinje myocyte adhesion involved in cell communication GO:0086073 9.49 DSC2 DSG2
19 Notch receptor processing GO:0007220 9.43 NCSTN PSEN1 PSENEN
20 amyloid precursor protein catabolic process GO:0042987 9.33 NCSTN PSEN1 PSENEN
21 Notch receptor processing, ligand-dependent GO:0035333 9.13 NCSTN PSEN1 PSENEN
22 amyloid-beta formation GO:0034205 8.8 NCSTN PSEN1 PSENEN

Molecular functions related to Hidradenitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell adhesive protein binding involved in bundle of His cell-Purkinje myocyte communication GO:0086083 8.62 DSC2 DSG2

Sources for Hidradenitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....